Recent data indicate that inhibition of KDM4B reduces global levels of both H3K9me3 and H3K27me3, resensitizing CRPC cells to the AR pathway inhibitor enzalutamide and inhibiting tumor growth (84). The gene discussed is AR; the disease is neoplasm.